Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canada’s Microbix Biosystems To Help China Become World Vaccine Powerhouse

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Toronto-headquartered Microbix Biosystems plans to begin building Asia's largest influenza vaccine production facility near the birthplace of China's Chairman Mao Zedong in 2009, in a partnership with provincial leaders, according to Microbix CEO Bill Gastle

You may also be interested in...

China’s Health System Reforms Set To Spark Hospital Construction Boom And Boost Medical Device Makers

[Editor's note: This is part two in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes and access to medicines. Part one appeared in PharmAsia News on Oct. 30, 2008.]

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts